CS
MBX

Candriam SCA’s MBX Biosciences MBX Stock Holding History

Candriam SCA’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.79M Buy
+294,374
New +$10M 0.05% 300

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Candriam SCA's MBX Position: Q1 2026 in Review

Candriam SCA opened a new position in MBX Biosciences (MBX) in Q1 2026: 294,374 shares worth $8.79M. The stake represents 0.05% of the portfolio and ranks #300 among its holdings.

157 funds tracked by Wall St. Rank hold MBX as of Q1 2026.

  • Candriam SCA held 294,374 shares of MBX Biosciences worth $8.79M as of Q1 2026.
  • MBX Biosciences was a new Candriam SCA position in Q1 2026.
  • MBX Biosciences made up 0.05% of Candriam SCA's portfolio in Q1 2026, its #300 holding.
  • 157 funds tracked by Wall St. Rank held MBX Biosciences as of Q1 2026.

Based on Candriam SCA's 13F filing for Q1 2026, filed 30 Apr 2026.